TY - JOUR
KW - Adolescent
KW - Adult
KW - Aged
KW - Child
KW - Combined Modality Therapy
KW - Comorbidity
KW - Diagnostic and Statistical Manual of Mental Disorders
KW - Evidence-Based Medicine
KW - Female
KW - Humans
KW - Male
KW - Mental Disorders/drug therapy/epidemiology
KW - Pregnancy
KW - Pregnancy Complications/drug therapy/epidemiology
KW - Psychotherapy
KW - Substance Withdrawal Syndrome/drug therapy/epidemiology
KW - Substance-Related Disorders/drug therapy/epidemiology/therapy
KW - United Kingdom
AU - A. R. Lingford-Hughes
AU - S. Welch
AU - L. Peters
AU - D. J. Nutt
AU - Expert Reviewers Group British Association for Psychopharmacology
A1 - 
AB - The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people.
BT - Journal of psychopharmacology (Oxford, England)
C5 - Opioids & Substance Use; Education & Workforce
CP - 7
CY - United States
DO - 10.1177/0269881112444324
IS - 7
JF - Journal of psychopharmacology (Oxford, England)
N2 - The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people.
PP - United States
PY - 2012
SN - 1461-7285; 0269-8811
SP - 899
EP - 952
EP - 
T1 - BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
T2 - Journal of psychopharmacology (Oxford, England)
TI - BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
U1 - Opioids & Substance Use; Education & Workforce
U2 - 22628390
U3 - 10.1177/0269881112444324
VL - 26
VO - 1461-7285; 0269-8811
Y1 - 2012
ER -